News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Essential medicines were made available to more than 150 countries around the world during the pandemic
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
_256_384.jpg)
Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.
At the latest Indian Pharma Post E-Conference, leading experts highlighted the need for accredited trial sites, skilled investigators, digital ecosystems, and greater public trust
Pharma industry veteran brings more than two decades of experience in sales, marketing, business development, and global market expansion to his new leadership role
Pharma industry veteran brings extensive experience in commercial strategy, business growth, and market leadership to his expanded role at Cipla
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
Subscribe To Our Newsletter & Stay Updated
